CRSP - Better Growth Stock: Axsome vs. CRISPR Therapeutics
2023-04-16 05:30:00 ET
If you're looking to add some growth to your portfolio, you may find it in biotech stocks. Two in particular offer investors a terrific opportunity right now. That's because both of them are in the early stages of their growth story. And this means early investors could benefit from these stocks for quite some time.
I'm talking about Axsome Therapeutics (NASDAQ: AXSM) and CRISPR Therapeutics (NASDAQ: CRSP) . Axsome launched its first two products last year -- and may have more on the way. CRISPR recently requested regulatory approval for a product candidate with blockbuster potential. Which of these innovative biotechs makes the better buy right now? Let's find out.
Axsome bought the sleep disorder drug Sunosi from Jazz Pharmaceuticals and started selling it last spring. The company launched a product from its own pipeline -- antidepressant Auvelity -- soon afterward. Both drugs are expected to bring in peak revenue of more than $1 billion.
For further details see:
Better Growth Stock: Axsome vs. CRISPR Therapeutics